Campbell Bradley L, an insider at Amicus Therapeutics Inc (FOLD), sold 1,137,282 shares of the company's stock at a price of $10.04 per share on November 23, 2025. The total transaction value amounted to $11.42 million. Following this sale, Campbell retains 1,137,282 shares in the company.
Amicus Therapeutics, based in Princeton, New Jersey, focuses on developing therapies for metabolic diseases. The company has a market capitalization of $3.1 billion and reported an EPS of -0.05. Its two marketed therapies include Galafold, an oral treatment for Fabry disease, and Pombiliti + Opfolda, a combination therapy for late-onset Pompe disease. Upcoming earnings reports are scheduled for April 29, 2026, with an EPS estimate of $0.03 and revenue estimate of $167.9 million, followed by a report on July 29, 2026, with an EPS estimate of $0.06 and revenue estimate of $184.7 million.
Insider transactions, such as this sale, are reported to the SEC and can provide insight into executives' perspectives on their company's stock. However, such sales may occur for various reasons, including personal financial needs or tax planning. Investors should consider insider activity in conjunction with other market factors rather than in isolation.